1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

PRESCRIPTION PAIN DRUGS–INCLUDING OPIOID, ANTICONVULSANT, INJECTABLE/INHALED, TOPICAL/TRANSDERMAL, MEDICAL MARIJUANA–GLOBAL MARKETS, COMPETITORS AND OPPORTUNITIES: 2015-2020 ANALYSIS AND FORECASTS

  • September 2015
  • 283 pages
  • Amadee and Company
Report ID: 3216405

Summary

Table of Contents

Search Inside

Abstract

Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage. At some point, everyone experiences pain. Pain may be described according to severity (mild, moderate, severe), duration (acute or chronic) or type (nociceptive, inflammatory, neuropathic).

Mild-to-moderate pain, such as orthopedic and soft tissue-related pain, generally is treated with NSAIDs, celecoxib (Pfizer’s Celebrex), or mild opioid analgesics, such as tramadol. Moderate-to-moderately severe pain, such as post-operative pain, orthopedic pain, and chronic back pain, generally is treated with opioid analgesics, including short-acting opioids such as hydrocodone, oxycodone, oxymorphone, and morphine, as well as extended-release formulations of oxycodone, oxymorphone, and morphine. Severe pain, including post-operative and cancer pain, generally is treated with fentanyl products, such as Duragesic, Actiq, and Fentora, as well as morphine formulations, such as Avinza and Kadian.

This report deals with prescription drugs used to treat pain. While the Prescription Pain Drug market is relatively small and very mature, there are many new products coming online that have significant sales potential including Pfizer’s Remoxy, Oxycodone NT and Embeda drugs, AcelRx’s Zlaviso, Eagalet Corp’s Oxayado, Endo/BDSI’s Buprenorphine, GW Pharmaceuticals’ Sativex, Insys’ Subsys and dronabinol OS, Marinus’ ganaxolone, as well as Bedrocan’s and Tweed’s medical marijuana offerings, among others.

Ultimately however, Prescription Pain Drugs are very important because without them life would be intolerable for millions of people.

For example, an estimated 50% of cancer patients experience some form of pain, which increases to 90% for patients with advanced-stage disease. Even worse, as many as 50% of patients may be under-treated for cancer-associated pain.

This report provides:

- In-depth discussion of Pain Pharmacology and Analgesia.
- Overview of the Prescription Pain Drugs market by product class, applications, producer market shares, market drivers and R&D pipelines.
- Comprehensive analysis of the markets for Opioid, Neuropathic, Injectable/Inhaled, Topical/Transdermal and Medical Marijuana drugs used to treat pain.

Additionally, detailed profiles of 32 leading companies involved in the Prescription Pain Drugs industry are given. The report also includes 46 tables and 30 figures.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Non-opioid Pain Patch Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • June 2017
  • by Transparency Market Research

Global Non-opioid Pain Patch Market: Overview Transdermal drug delivery systems (TDDS) is a systemic drug therapy approach which eliminates the risk of gastro-intestinal adverse reactions. The low concentrations ...

Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse

  • $ 4995
  • Industry report
  • June 2017
  • by GBI Research

Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse Summary Pain can be classified into three main categories. ...

Arthralgia Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • April 2017
  • by GlobalData

Arthralgia Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Arthralgia Global Clinical Trials Review, H1, 2017" provides an overview of Arthralgia clinical trials ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.